An Abbott Laboratories processing plant in Sturgis, Mich being investigated for cases of infant illness is being allowed to release some product that was processed before it was shut down.
Certain goods designed for infants and people with specific medical issues will be given out for free.
Abbott officials claimed they're doing it at the FDA's request to help with shortages of these specialty feeding items.
After a recall of Similac infant formula and other products in February, the Sturgis plant was forced to shut down. Cronobacter bacteria had infected many infants, one of whom died; cronobacter was identified in their systems and the formula they had drunk. Cronobacter bacteria were discovered in the factory during an inspection.
However, further examination revealed that the cronobacter strain that caused the infections was not the same as the one detected in the plant and that no food-contact surfaces had been contaminated.
On a case-by-case basis, Abbott is issuing cases of a nutrition supplement for people with uncommon metabolic diseases and others. The corporation stated that it is doing so at the FDA's request to assist reduce shortages.


Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
South Korea Assures U.S. on Trade Deal Commitments Amid Tariff Concerns
Trump Signs Executive Order Threatening 25% Tariffs on Countries Trading With Iran
South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom
Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Gold Prices Slide Below $5,000 as Strong Dollar and Central Bank Outlook Weigh on Metals
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals 



